Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (91-100 of 760) with videos related to

Pageof 76
Sort By:
Expert Review of Clinical Pharmacology|April 15, 2023
How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?Mattia Galli, Dominick J Angiolillo
Journal of Thrombosis and Thrombolysis|August 29, 2014
Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemmaJung Rae Cho, Dominick J Angiolillo
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 25, 2013
Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agentsDominick J Angiolillo, José Luis Ferreiro
Interventional Cardiology Clinics|November 26, 2016
Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary InterventionDominick J Angiolillo, Matthew J Price
Journal of the American College of Cardiology|April 28, 2018
Pharmacogenomic Testing to Select Antiplatelet TherapyMatthew J Price, Dominick J Angiolillo
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 10, 2016
Clinical Pharmacology and Cardiovascular Safety of NaproxenDominick J Angiolillo, Steven M Weisman
JACC. Cardiovascular Interventions|June 17, 2019
Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation: The Certainty of UncertaintyDominick J Angiolillo, Andres M Pineda
Revista Espanola De Cardiologia|January 22, 2010
Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directionsDominick J Angiolillo, José Luis Ferreiro
Circulation. Cardiovascular Interventions|June 21, 2012
New directions in antiplatelet therapyJosé Luis Ferreiro, Dominick J Angiolillo
Current Pharmaceutical Design|June 26, 2012
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery diseaseJose Luis Ferreiro, Dominick J Angiolillo
Pageof 76

Showing results (91-100 of 760) with videos related to

Sort By:
Pageof 76
Expert Review of Clinical Pharmacology|April 15, 2023
How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?Mattia Galli, Dominick J Angiolillo
Journal of Thrombosis and Thrombolysis|August 29, 2014
Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemmaJung Rae Cho, Dominick J Angiolillo
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 25, 2013
Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agentsDominick J Angiolillo, José Luis Ferreiro
Interventional Cardiology Clinics|November 26, 2016
Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary InterventionDominick J Angiolillo, Matthew J Price
Journal of the American College of Cardiology|April 28, 2018
Pharmacogenomic Testing to Select Antiplatelet TherapyMatthew J Price, Dominick J Angiolillo
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 10, 2016
Clinical Pharmacology and Cardiovascular Safety of NaproxenDominick J Angiolillo, Steven M Weisman
JACC. Cardiovascular Interventions|June 17, 2019
Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation: The Certainty of UncertaintyDominick J Angiolillo, Andres M Pineda
Revista Espanola De Cardiologia|January 22, 2010
Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directionsDominick J Angiolillo, José Luis Ferreiro
Circulation. Cardiovascular Interventions|June 21, 2012
New directions in antiplatelet therapyJosé Luis Ferreiro, Dominick J Angiolillo
Current Pharmaceutical Design|June 26, 2012
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery diseaseJose Luis Ferreiro, Dominick J Angiolillo
Pageof 76